Shares

PharmaShots Interview: Abbott’s Suela Sulo Shares Insights on the Model of Care Addressing Malnutrition Across the Continuum of Care

In an interview with PharmaShots, Suela Sulo, Ph.D., M.S., Director of Global Health Economics, Outcomes Research and Policy at Abbott shared her views on how this study will shift the way to approach nutrition across the continuum of care. Shots: A study published in the Journal of Primary Care and Community Health has shown that …

PharmaShots Interview: Abbott’s Suela Sulo Shares Insights on the Model of Care Addressing Malnutrition Across the Continuum of Care Read More »

With 5 patents under its belt, RCM tech company Ensemble Health Partners files for IPO

The company, which provides revenue cycle management solutions for providers, is filing for the IPO less than two years after Bon Secours Mercy Health sold its majority stake in Ensemble to private equity firm Golden Gate Capital. Per the filing, the company aims to raise $100 million, but that is likely a placeholder figure.

ViewPoints Interview: Dr. Robert Koenekoop Shares Insights on Stellar Study Evaluating ProQR’s QR-421a

In an interview with PharmaShots, Dr. Robert Koenekoop, MD, PhD, Professor of Pediatric Surgery, Human Genetics and Adult Ophthalmology at McGill University’s Montreal Children’s Hospital shared his views on the clinical data of the trial and shed light on how RNA therapies work in eye disorders? Shots: QR-421a demonstrated a concordant benefit in multiple measures …

ViewPoints Interview: Dr. Robert Koenekoop Shares Insights on Stellar Study Evaluating ProQR’s QR-421a Read More »

ViewPoints Interview: Artelo Bio’s Dr. Saoirse O’Sullivan Shares Insights on Synthetic Cannabinoid for Cancer Anorexia

In an interview with PharmaShots, Dr. Saoirse O’Sullivan, Ph.D., Scientific Advisor to Artelo Bio shares insights on new cannabinoids, their relevancy, and the other opportunities that can arise from modulating the ECS. Shots: The endocannabinoid system is a network of neurotransmitters and receptors throughout the body that can have a significant impact on improving human health …

ViewPoints Interview: Artelo Bio’s Dr. Saoirse O’Sullivan Shares Insights on Synthetic Cannabinoid for Cancer Anorexia Read More »

ViewPoints Interview: Codiak BioSciences’ Douglas E. Williams Shares Insight on the Potential of its Engineered Exosomes

In an interview with PharmaShots, Douglas E. Williams, Ph.D., President and Chief Executive Officer of Codiak BioSciences shares insights on the potential of engineered exosomes and the data presented at SITC 2020. Shots: Codiak demonstrated the potential of engineered exosomes –  extracellular vesicles that act like the body’s FedEx delivery trucks to carry messengers between …

ViewPoints Interview: Codiak BioSciences’ Douglas E. Williams Shares Insight on the Potential of its Engineered Exosomes Read More »

ViewPoints Interview: Biogen’s Monica Mann Shares Insight on Plegridy to Treat Multiple Sclerosis

In an interview with PharmaShots, Monica Mann, Head of Global Medical, Multiple Sclerosis at Biogen shares her views on the Plegridy and how it works on MS patients. She also shed light on the approval of the therapy in the US and EU. Shots: The approval of Plegridy (IM) by the EC and the US …

ViewPoints Interview: Biogen’s Monica Mann Shares Insight on Plegridy to Treat Multiple Sclerosis Read More »

ViewPoints Interview: Leap Therapeutic’s Douglas Onsi Shares Insight on its Lead Candidate, DKN-01

In an interview with PharmaShots, Douglas Onsi, CEO and President of Leap Therapeutics shares insights on the clinical data of DKN-01 along with its mechanism. He also highlights the company’s growth, plans, goal etc. Shots: DKK1 is a secreted protein that modulates cell signaling pathways known as the Wnt signaling pathways, as well as the …

ViewPoints Interview: Leap Therapeutic’s Douglas Onsi Shares Insight on its Lead Candidate, DKN-01 Read More »

ViewPoints Interview: Fluxergy’s Tej Patel Shares Insight on Multimodal Diagnostic System

In an interview with PharmaShots, Tej Patel, CEO of Fluxergy shared his views on Fluxergy’s CE Marking and how it will democratize healthcare while creating better clinical outcomes. Shots: Fluxergy’s One-hour COVID-19 test requires less than 2-3 minutes of hands-on time and provides lab-quality RT-PCR test results within an hour. The Fluxergy analyzer is a …

ViewPoints Interview: Fluxergy’s Tej Patel Shares Insight on Multimodal Diagnostic System Read More »

ViewPoints Interview: Aravive’ s Dr. Gail McIntyre Shares Insight on AVB-500 and its Potential Against ccRCC

In an interview with PharmaShots, Dr. Gail McIntyre, CEO of Aravive shared her views on the AVB-500, its potential against ccRCC, and the design of the clinical trial evaluating the therapy. He also shed light on epidemiology of Clear Cell Renal Cell Carcinoma. Shots: AVB-500 is being evaluated in ccRCC, has been tested in preclinical …

ViewPoints Interview: Aravive’ s Dr. Gail McIntyre Shares Insight on AVB-500 and its Potential Against ccRCC Read More »

ViewPoints Interview: Marc Meachem Shares Insight on the ViiV’s 2021 Commitment to the Community

In an interview with PharmaShots, Marc Meachem, Head of US External Affairs at ViiV Healthcare shared his views on the company’s approach towards the community. He also shed light on the grants and funding received for the betterment of HIV patients. Shots: ViiV Healthcare is doubling its community investments in 2021 with the goal of …

ViewPoints Interview: Marc Meachem Shares Insight on the ViiV’s 2021 Commitment to the Community Read More »

ViewPoints Interview: NeuBase Therapeutics’ Dietrich Stephan Shares Insight on its Approach to Genetic Medicine

In an interview with PharmaShots, Dietrich Stephan, Ph.D., CEO of NeuBase Therapeutics shared his views on the importance of preclinical in vivo data for PATrOL-enabled anti-gene for myotonic dystrophy type 1. Shots: NeuBase announced in vitro and in vivo data for its DM1 program, demonstrating the potential of its genetic medicine platform to target the …

ViewPoints Interview: NeuBase Therapeutics’ Dietrich Stephan Shares Insight on its Approach to Genetic Medicine Read More »

ViewPoints Interview: Eli Lilly’s Marie Schiller Shares Insight on the Collaboration with Welldoc on New Version of BlueStar App

In an interview with PharmaShots, Marie Schiller Vice President of Product Development for Connected Care and Insulins at Lilly shared her views on its collaboration with Welldoc to integrate Welldoc’s insulin management technology into Lilly’s connected insulin solutions. Shots: Lilly and Welldoc are teaming up to create a new version of Welldoc’s BlueStar app which will be …

ViewPoints Interview: Eli Lilly’s Marie Schiller Shares Insight on the Collaboration with Welldoc on New Version of BlueStar App Read More »

Report: Bright Health eyes $1B IPO

Insurance startup Bright Health is reportedly planning to raise up to $1 billion in an IPO that will be launched in the second quarter of 2021. The company, which provides several insurance products as well as an IT platform, could be valued at more than $10 billion, Bloomberg reported.

ViewPoints Interview: Takeda’s Nirav Desai Shares Insight on Data of TAK-721 Presented at ACG 2021

In an interview with Nirav Desai, Global Clinical Development Lead at Takeda shared his views on Tak-721 presented at ACG 2021 and its implications for patients and HCPs. The presentation includes post hoc analyses from a 12-week, randomized, double-blind, placebo-controlled Phase 3 clinical trial that investigated the safety and efficacy of BOS in patients with EoE 11 to 55 …

ViewPoints Interview: Takeda’s Nirav Desai Shares Insight on Data of TAK-721 Presented at ACG 2021 Read More »

ViewPoints Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment

In an interview with PharmaShots, Dr. Todd D. Cohen, M.D., VP Medical Affairs and Medical Director of Urology at Myriad Genetics shared his views on the ability of a biomarker test to predict which men with aggressive prostate cancer will benefit from advanced hormonal therapy and which men with lower-risk prostate cancer can safely avoid such …

ViewPoints Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment Read More »

ViewPoints Interview: Fusion Pharma’s John Valliant Shares Insight on its Collaboration with AstraZeneca

In an interview with PharmaShots, John Valliant, CEO at Fusion Pharma shared his views on the company’s agreement with AstraZeneca, signed in Nov 2020. He also shared in-depth information about the company’s TATs platform & Fast-Clear linker technology and provide a glance at Fusion’s portfolio. Shots: Fusion to receive $5M up front and $40M as …

ViewPoints Interview: Fusion Pharma’s John Valliant Shares Insight on its Collaboration with AstraZeneca Read More »

ViewPoints Interview: SiO2’s Lawrence Ganti Shares Insight on the Efforts to Scale Up the Manufacturing of Vials for COVID-19 Vaccines

In an interview with PharmaShots, Lawrence Ganti, President & Chief Business Officer at SiO2 Materials Science shared his views on the efforts to scale up the manufacturing of vials to combat COVID-19. Additionally, he also shared the benefits of using SiO2’s smart vials and shed light on barrier technology. Shots: SiO2 received a $143M investment …

ViewPoints Interview: SiO2’s Lawrence Ganti Shares Insight on the Efforts to Scale Up the Manufacturing of Vials for COVID-19 Vaccines Read More »

ViewPoints Interview: Biogen’s Wildon R. Farwell Shares Insight on Phase 4 RESPOND Study of Spinraza

In an interview with PharmaShots, Wildon R. Farwell, M.D., MPH, Global Medical Head of Neuromuscular Diseases at Biogen shared his views on the P-IV RESPOND study that assesses the benefits of Spinraza in patients treated with Zolgensma. Shots: RESPOND is a two-year, open-label study to evaluate the efficacy and safety of Spinraza (nusinersen) in infants …

ViewPoints Interview: Biogen’s Wildon R. Farwell Shares Insight on Phase 4 RESPOND Study of Spinraza Read More »

ViewPoints Interview: Abbott’s Allen Burton Shares Insight on NeuroSphere myPath App

In an interview with PharmaShots, Allen Burton, M.D., Medical Director at Abbott Neuromodulation shared his views on the NeuroSphere myPath App which is designed to track and report pain relief in chronic pain patients. Shot: The app will record pain relief during the device trial period with SCS or DRG therapy, simplifying reporting outcomes & …

ViewPoints Interview: Abbott’s Allen Burton Shares Insight on NeuroSphere myPath App Read More »

ViewPoints Interview: Merz Aesthetics’ Dr. Terri Phillips Shares Insight on GP Campaign for Xeomin

In an interview with PharmaShots, Dr. Terri Phillips, Chief Medical Affairs Officer at Merz Aesthetics shared her views on the new campaign with Gwyneth Paltrow for its flagship product Xeomin. She also shed light on Medical Aesthetic treatments during the pandemic and how Merz is working to meet the demand. Shots: Merz Aesthetics collaborates with …

ViewPoints Interview: Merz Aesthetics’ Dr. Terri Phillips Shares Insight on GP Campaign for Xeomin Read More »

ViewPoints Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen, the First Treatment for Leber Congenital Amaurosis 10 (LCA10)

In an interview with PharmaShots, Daniel A. de Boer of ProQR shared his views on P-II/III pivotal trial of Sepofarsen to treat the root cause of a rare eye disease, Leber congenital amaurosis 10 (LCA10) Shots: The Illuminate P-II/III trial of sepofarsen is a double-masked, randomized, controlled, multiple-dose study to evaluate if sepofarsen is effective …

ViewPoints Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen, the First Treatment for Leber Congenital Amaurosis 10 (LCA10) Read More »

ViewPoints Interview: ViiV Healthcare’s Dr. Kimberly Smith Shares Insight on Davato (dolutegravir/lamivudine)

In an interview with PharmaShots, Dr. Kimberly Smith, Head of Research & Development, ViiV Healthcare shed light on the FDA’s approval and the 3yrs. data of Dovato. Shots: Dovato (dolutegravir/lamivudine) is the first complete, once-daily, single-tablet, 2DR for the treatment of HIV-1 infection in both treatment-naïve and virologically suppressed adults In July 2020, the FDA …

ViewPoints Interview: ViiV Healthcare’s Dr. Kimberly Smith Shares Insight on Davato (dolutegravir/lamivudine) Read More »

ViewPoints Interview: Legend’s Ying Huang Shares Insight on ASH 2020 Data and Initiation of BLA Rolling Submission for Cilta-cel

In an interview with PharmaShots, Ying Huang, Ph.D., CEO and CFO of Legend Biotech shed light on the clinical data following the rolling submission of BLA for Cilta-cel. He also shared insight on Legends’ collaboration with Janssen. Shots: The submission of BLA was based on results from the P-Ib/II CARTITUDE-1 study of cilta-cel, which were …

ViewPoints Interview: Legend’s Ying Huang Shares Insight on ASH 2020 Data and Initiation of BLA Rolling Submission for Cilta-cel Read More »

ViewPoints Interview: GSK’s Steve Bradford Shares Insight on Benlysta

In an interview with PharmaShot, Steve Bradford, Vice President, Medicines Commercialization Leader at GSK shed light on the US FDA’s approval of Benlysta as the first and only approved treatment for both lupus and adult patients with active LN who are receiving standard therapy. Shots: The US FDA has approved GSK’s Benlysta (belimumab) as the …

ViewPoints Interview: GSK’s Steve Bradford Shares Insight on Benlysta Read More »

ViewPoints Interview: ALX Oncology’s Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework

In an interview with PharmaShot, Dr. Sophia Randolph, Chief Medical Officer of ALX Oncology shared her views on the ALX Oncology’s collaboration with Zymework for evaluating the combination with ALX148 and zanidatamab for patients with advanced HER2-expressing breast cancer and other HER2-expressing solid tumors. Shots: Zymeworks will conduct a P-Ib study to assess the safety …

ViewPoints Interview: ALX Oncology’s Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework Read More »

ViewPoints Interview: Deciphera’s Mathew L. Sherman Shares Insight on Data of QINLOCK and DCC-3014 Presented at CTOS 2020

In an interview with PharmaShots, Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera shed light on encouraging preliminary results from the ongoing P-I/II study of DCC-3014 in TGCT patients and also presented the data of QINLOCK at CTOS 2020 Shots: Deciphera presented encouraging preliminary results from the ongoing Phase 1/2 …

ViewPoints Interview: Deciphera’s Mathew L. Sherman Shares Insight on Data of QINLOCK and DCC-3014 Presented at CTOS 2020 Read More »

ViewPoints Interview: Zogenix’s Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

In an interview with PharmaShots, Bradley Galer, M.D., Chief Medical Officer at Zogenix shed light on data supporting the regulatory application and what the EU approval of Fintepla will mean in terms of reducing the high physical, emotional, and financial burden associated with the disease. Shots: Fintepla was approved by the EC in Dec’2020 as …

ViewPoints Interview: Zogenix’s Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution) Read More »

ViewPoints Interview: Medicago’s Nathalie Landry Shares Insight on Plant-Derived Vaccine for COVID-19

In an interview with PharmaShots, Nathalie Landry, Executive Vice President, Scientific and Medical Affairs at Medicago shared her views on positive results of P-I clinical trial results for its plant-derived COVID-19 vaccine.  Shots: The results of the trial demonstrated that 100% of participants developed a promising antibody response after two doses of Medicago’s COVID-19 adjuvanted …

ViewPoints Interview: Medicago’s Nathalie Landry Shares Insight on Plant-Derived Vaccine for COVID-19 Read More »

ViewPoints Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020

In an interview with PharmaShots, Dr. Andreas Harstrick, Chief Medical Officer at Affimed shared his views on updated clinical data related to their lead innate cell engager AFM13 at the virtual 62nd American Society of Hematology (ASH) annual meeting. Shots: The study showed an ORR of 42% (6/14 patients) and demonstrated clinical activity in two …

ViewPoints Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020 Read More »

ViewPoints Interview: Tilak Healthcare’s Edouard Gasser Shares Insights on OdySight

In a recent interview with PharmaShots, Edouard Gasser, CEO of Tilak Healthcare shared his views on OdySight, which is the first medical game to monitor eyesight for patients with chronic eye diseases. Shots: OdySight is a free mobile game and medical-grade application used to remotely monitor patients suffering from chronic maculopathies such as AMD, macular …

ViewPoints Interview: Tilak Healthcare’s Edouard Gasser Shares Insights on OdySight Read More »

ViewPoints Interview: BMS Foundation’s Patricia Mae Doykos Shares Insights on COVID Advocacy Exchange

In a recent interview with PharmaShots, Patricia Mae Doykos, Lead, Health Equity Initiative, and Director, BMS Foundation at Bristol Myers Squibb shared her views on the promotion of health equity and improvement in health outcomes of populations disproportionately affected by serious diseases and conditions. Shots: CAE is a virtual platform that convenes advocacy groups, patients, …

ViewPoints Interview: BMS Foundation’s Patricia Mae Doykos Shares Insights on COVID Advocacy Exchange Read More »

ViewPoints Interview: Janssen’s Andrew Greenspan Shares Insights on the Data Presented at ACR2020

In a recent interview with PharmaShots, Andrew Greenspan, MD, VP Medical Affairs of Janssen Immunology shared his views on Janssen’s commitment to advance research in rheumatic disease. Shots: Janssen presented clinical trial results in 35 abstracts featuring findings across PsA, RA, and SLE at ACR Convergence 2020 Virtual Scientific Program Sixteen abstracts focus on Tremfya …

ViewPoints Interview: Janssen’s Andrew Greenspan Shares Insights on the Data Presented at ACR2020 Read More »

ViewPoints Interview: GSK’s Dr. Riju Ray Shares Insights on the Role of Community-Based Pulmonologists in Improving COPD Management Among PCPs

In a recent interview with PharmaShots, Dr. Riju Ray, MD, PhD, Senior Medical Lead at GSK, leading US medical affairs across asthma and COPD shared his views on how community-based pulmonologists are improving COPD management and education among referring PCPs. Shots: Pulmonologists identified 12 strong to moderate predictors of future COPD exacerbations, some of which …

ViewPoints Interview: GSK’s Dr. Riju Ray Shares Insights on the Role of Community-Based Pulmonologists in Improving COPD Management Among PCPs Read More »

ViewPoints Interview: Genentech’s Ted Omachi Shares Insight on the US FDA’s Approval of Xolair in Nasal polyps

In a recent interview with PharmaShots, Ted Omachi, Global Development Leader for Xolair, and Senior Medical Director of Product Development for Immunology, Genentech shared his views on the approval of Xolair in the US. Shots: The approval is based on P-III POLYP 1 & 2 trials assessing Xolair vs PBO in 138 & 127 adult …

ViewPoints Interview: Genentech’s Ted Omachi Shares Insight on the US FDA’s Approval of Xolair in Nasal polyps Read More »

ViewPoints Interview: ViiV Healthcare’s Kimberly Smith Shares Insight on Data of Long-Acting Cabotegravir and Rilpivirine Presented at IDWeek 2020

In a recent interview with PharmaShots, Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare shared information on the positive findings presented at the 2020 Infectious Diseases Society of America (IDWeek) and the impact of COVID-19 on the development of long-acting cabotegravir and rilpivirine. Shots: The company reported the positive findings of …

ViewPoints Interview: ViiV Healthcare’s Kimberly Smith Shares Insight on Data of Long-Acting Cabotegravir and Rilpivirine Presented at IDWeek 2020 Read More »

ViewPoints Interview: Neoleukin’s Daniel-Adriano Silva Shares Insight on Novel Protein Designed to Treat or Block SARS-COV-2

In a recent interview with PharmaShots Daniel-Adriano Silva, PhD, Co-founder and Vice President Head of Research at Neoleukin shared the significance and promise of the findings published in Science and discuss the details of its De Novo Protein Design Shots: NL-CVX1 (CTC-445.2d) demonstrated the ability to prevent infection of multiple human cell lines in vitro and …

ViewPoints Interview: Neoleukin’s Daniel-Adriano Silva Shares Insight on Novel Protein Designed to Treat or Block SARS-COV-2 Read More »

ViewPoints Interview: Kezar’ Noreen Henig Shares Insight on Therapeutic Potential of KZR-616

In a recent interview with PharmaShots, Noreen Henig, Chief Medical Officer at Kezar Life Sciences shared information on clinical and pre-clinical data supporting the potential of KZR-616 to positively affect multiple drivers of immune-mediated diseases. Shots: The poster presented at ACR 2020 includes additional patient-weeks of safety and tolerability data compared to prior data presentations …

ViewPoints Interview: Kezar’ Noreen Henig Shares Insight on Therapeutic Potential of KZR-616 Read More »

ViewPoints Interview: Cellares’ Fabian Gerlighaus Shares Insight on Cell Shuttle

In a recent interview with PharmaShots, Fabian Gerlighaus, Co-Founder and CEO of Cellares, shared information on Cellares partnership with Fred Hutchinson Cancer Research Center and unveils how the company is working to get patients the cell therapies they need. Shots: Cellares’ collaboration with Fred Hutchinson Cancer Research Center is a part of EAPP. Fred Hutch …

ViewPoints Interview: Cellares’ Fabian Gerlighaus Shares Insight on Cell Shuttle Read More »

ViewPoints Interview: Novocure’s William F. Doyle Shares Insight on Company’s Accomplishments in the Treatment of Glioblastoma and Mesothelioma

In a recent interview with PharmaShots, William F. Doyle, Executive Chairman at Novocure shared information about the company’s activities in the field of glioblastoma and mesothelioma. He also discussed the company’s technology, Tumor Treating Fields (TTFields), and its potential for broad applicability across solid tumors. Shots: Novocure is a global oncology company working to extend …

ViewPoints Interview: Novocure’s William F. Doyle Shares Insight on Company’s Accomplishments in the Treatment of Glioblastoma and Mesothelioma Read More »

ViewPoints Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM

In a recent interview with PharmaShots, Julie Foster, Vice President, Global Customer Experience of the Diabetes business at Medtronic, shares information about recent and upcoming announcements for the company. Shots: The integration of real-time CGM data into the smart insulin pen app follows the acquisition of Companion Medical’s InPen to the Medtronic portfolio, as of Sept’2020 The …

ViewPoints Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM Read More »

ViewPoints Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM

In a recent interview with PharmaShots, Julie Foster, Vice President, Global Customer Experience of the Diabetes business at Medtronic, shares information about recent and upcoming announcements for the company. Shots: The integration of real-time CGM data into the smart insulin pen app follows the acquisition of Companion Medical’s InPen to the Medtronic portfolio, as of Sept’2020 The …

ViewPoints Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM Read More »

ViewPoints Interview: Duke’s Andrea Taylor Shares Insight on Launch And Scale Speedometer

In a recent interview with PharmaShots, Andrea Taylor, Researcher at Launch And Scale Speedometer shared her insights and highlights on data how rich countries’ shopping spree for COVID-19 vaccines means fewer vaccinations for billions in low-income countries Shots: The Launch and Scale Speedometer project aims to systematically analyze the factors that support or hinder the …

ViewPoints Interview: Duke’s Andrea Taylor Shares Insight on Launch And Scale Speedometer Read More »

ViewPoints Interview: Caris Life Sciences’ Dr. Spetzler Shares Insight on AI-Powered Clinico-Genomic Data Platform

In a recent interview with PharmaShots, Dr. Spetzler, President and Chief Scientific Officer of Caris Life Sciences shared his insights and highlights on data of the launch of CODEai. Shots: CODEai is a real-world clinico-genomic data platform that integrates Caris Life Sciences’ extensive catalog of molecular data with cancer treatment information and clinical outcomes data …

ViewPoints Interview: Caris Life Sciences’ Dr. Spetzler Shares Insight on AI-Powered Clinico-Genomic Data Platform Read More »

ViewPoints Interview: True Digital Surgery’s Aidan Foley Shares Insight on Aesculap Aeos Robotic Digital Microscope

In a recent interview with PharmaShots, Aidan Foley, Chairman and Chief Operating Officer of True Digital Surgery share his insights and highlights on data of Aesculap Aeos Robotic Digital Microscope. Shots: The robotic digital microscope enables surgeons to execute precision movements in neurosurgery, spine, and ear, nose, and throat operations, through a multi-axis robotic arm. …

ViewPoints Interview: True Digital Surgery’s Aidan Foley Shares Insight on Aesculap Aeos Robotic Digital Microscope Read More »

ViewPoints Interview: Dicerna’s Doug Fambrough Shares Insight on Nedosiran Data Presented at ASN Week 2020

In a recent interview with PharmaShots, Doug Fambrough, Ph.D., President and CEO of Dicerna shares his insights and highlights on data of Nedosiran presented at ASN Week 2020. Shots: All participants regardless of PH subtype, achieved normal or near-normal Uox excretion @day180, 92% participants (100% & 67% with PH1 & PH2) achieved normal Uox excretion …

ViewPoints Interview: Dicerna’s Doug Fambrough Shares Insight on Nedosiran Data Presented at ASN Week 2020 Read More »

ViewPoints Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Mirikizumab

In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Mirikizumab.  Shots: @52wks. ~60% achieved endoscopic responses (58.5% in IV dosing group and 58.7% in the SC group) while 45% + achieved PRO remission (46.3% in the IV group and 45.6% in the …

ViewPoints Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Mirikizumab Read More »

ViewPoints Interview: Takeda’s Andrea Stancati Shares Insights on Entyvio (vedolizumab) SC Formulation

In a recent interview with PharmaShots, Andrea Stancati, Vice President, Head GI Global Medical Franchise shares his insights and highlights of Entyvio (vedolizumab) Shots: The ongoing P-IIIb VISIBLE OLE study involves assessing of Entyvio (SC) in adult patients with UC or CD, following enrolment and participation in the VISIBLE 1 (UC) or VISIBLE 2 (CD) …

ViewPoints Interview: Takeda’s Andrea Stancati Shares Insights on Entyvio (vedolizumab) SC Formulation Read More »

ViewPoints Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep&amp Viral RNA UM Kit

In a recent interview with PharmaShots, Kai te Kaat, the Vice President, Head of Franchise Oncology, MDx at QIAGEN shares his insights and highlights on QIAprep&amp Viral RNA UM Kit. Shots: QIAGEN to launch the QIAprep&amp Viral RNA UM Kit, designed to simplify and accelerate PCR swab analysis and remove key testing bottlenecks for Covid-19 and other …

ViewPoints Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep&amp Viral RNA UM Kit Read More »

Insights+ Interview: Paige’s CEO, Leo Grady Shares Insights on its Series B Funding and the FDA’s 510(k) Clearance for FullFocus Viewer

Paige is a global digital pathology founded in 2017 by Thomas Fuchs, Dr. Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The company involves computational pathology products that are targeted for patients and their care teams for effective, more informed treatment decisions. Paige has developed a platform to deliver novel technology to pathologists to …

Insights+ Interview: Paige’s CEO, Leo Grady Shares Insights on its Series B Funding and the FDA’s 510(k) Clearance for FullFocus Viewer Read More »